Management and Treatment of Chronic Myeloid Leukemia

Management and Treatment of Chronic Myeloid Leukemia

Episodes

Specialty:

All

Year:

All

EP. 1: Introduction: Role of Genetic Testing in CML

January 14th 2015

EP. 2: Optimal Timing for Follow-up Mutation Testing in CML

January 14th 2015

EP. 3: Importance of Monitoring Patients With CML

January 14th 2015

EP. 4: Treatment Selection for Newly Diagnosed Patients With CML

January 14th 2015

EP. 5: First-Line Dasatinib in Chronic Myeloid Leukemia

January 14th 2015

EP. 6: Promises and Challenges of Ponatinib in CML

January 14th 2015

EP. 7: Dasatinib in the Second-Line CML Setting

January 14th 2015

EP. 8: First- and Second-Line Nilotinib in CML

January 14th 2015

EP. 9: Utilizing Second-Line Bosutinib in Ph+ CML

January 14th 2015

EP. 10: Ponatinib Effective in Resistant CML

January 14th 2015

EP. 11: Utilizing Omacetaxine in Chronic Myeloid Leukemia

January 14th 2015

EP. 12: Addressing Fluctuating BCR-ABL Levels in CML

January 14th 2015

EP. 13: Feasibility of TKI Discontinuation in CML

January 14th 2015

EP. 14: Final Comments From Panelists on Managing CML

January 14th 2015

Trending on OncLive

Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML

Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS

ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML

Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera

DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera